Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury With Buntanetap
H.C. Wainwright Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $30
Buy Rating Affirmed for Annovis Bio Amidst Promising Drug Developments and Strategic Team Expansion
Express News | HC Wainwright & Co. Reiterates Buy on Annovis Bio, Maintains $30 Price Target
Annovis Bio Says US FDA Approved Use of Neurodegeneration Drug Buntanetap in Crystalline Form
Express News | Annovis Bio Granted FDA Approval To Transition To New Crystal Form Of Buntanetap
Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap
Costco To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Thursday
H.C. Wainwright Maintains Annovis Bio(ANVS.US) With Buy Rating, Raises Target Price to $30
Buy Rating Affirmed: Promising Buntanetap Phase 3 Results and Increased Approval Probability Boost Annovis Bio's Price Target
HC Wainwright & Co. Maintains Buy on Annovis Bio, Raises Price Target to $30
Annovis Bio Analyst Ratings
Express News | Annovis Bio, Inc. : H.c. Wainwright Raises Target Price to $30 From $23
Annovis Bio Raises $7 Million From Warrant Exercises
Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Maxim Group Maintains Annovis Bio(ANVS.US) With Hold Rating
Maxim Group Sticks to Its Hold Rating for Annovis Bio (ANVS)
Express News | Annovis Bio Shares Resume Trade
Express News | Annovis Shares Halted On Circuit Breaker To Downside
Express News | NYSE Halt Annovis Bio Ord Add Info Lst $13.950000
No Data